BioSpace News Archive

Appointment is the Latest in a Focused Talent Strategy to Optimize Long-Term Shareholder Value and Build Recurring Revenue Base With Over 35 Patents and Patent Applications on Preclinical and Clinical Technologies, Company Seeks to Explore Out-Licensing and Collaborative Development Deals

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current update on the regulatory filing status for Fexapotide Triflutate (FT), Nymox’s first in class lead product for the treatment of benign prostatic hyperplasia (BPH). Substantial progress has been made and there are no material changes to the content of the planned applications. Unavoidable delays have been incurred in this project mainly due to the very lon

Kadiant, a mission-driven organization that provides high-quality Applied Behavior Analysis (ABA) therapy, speech therapy, diagnostic, and related services to individuals with autism spectrum disorder, announced today that Julie Zhuo has joined the company’s board of directors.

Internationally Renowned Med. Dents. and entrepreneurs Golnar and Haleh Abivardi unveil a suite of sustainably produced oral care products supercharged with the first tooth whitener that is actually good for your teeth.

Funding will support research to better understand and address the impact of COVID-19 on children’s mental health

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that the U.S. Phase 2 study with opaganib (Yeliva®, ABC294640)[1] in patients hospitalized with severe COVID-19 pneumonia has completed enrollment of the last patient in the study.

For the eighth consecutive year, Abbott (NYSE: ABT) has been named the industry leader in sustainability by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate sustainability.

Spiration Valve System Has Been Used to Treat More Than 500 Patients with Severe Emphysema - Their Stories Are an Inspiration to Others

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today highlighted new data on the mechanism of effect of tesamorelin presented in an oral presentation given today by Lindsay T. Fourman, M.D., of the Metabolism Unit, Department of Medicine, Massachusetts General Hospital, at The Liver Meeting® 2020 of the American Association for

Teneobio, Inc. and its affiliate TeneoFour, Inc. announced a Nature Metabolism publication of a proof of concept study by the Chini Laboratory describing the rejuvenation of energy metabolism in aged mice undergoing therapy with Teneobio’s CD38 blocker.